<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348514</url>
  </required_header>
  <id_info>
    <org_study_id>CPX-POM-01-001</org_study_id>
    <nct_id>NCT03348514</nct_id>
  </id_info>
  <brief_title>Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CicloMed LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cmed Clinical Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CicloMed LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, Phase I, multicenter, open label, dose escalation study to evaluate&#xD;
      the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered&#xD;
      IV in patients with any histologically- or cytologically-confirmed solid tumor type.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will initially employ an accelerated escalation design, with a single patient&#xD;
      enrolled in each cohort (i.e., Single-Patient Cohorts). The initial patient will receive&#xD;
      CPX-POM at a starting dose of 30 mg/m2. Doses will be escalated (doubling), until a ≥Grade 2&#xD;
      toxicity (with the exception of alopecia), is encountered. Subsequently that and all&#xD;
      subsequent cohorts will follow a classical &quot;3+3&quot; dose escalation design.&#xD;
&#xD;
      Note: Fosciclopirox is the generic name for CPX-POM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a Phase I, first-in-human, multicenter, open label, dose escalating study to evaluate the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered IV in patients with any histologically- or cytologically-confirmed solid tumor type.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM</measure>
    <time_frame>Up to 22 days for each cohort</time_frame>
    <description>The primary objective of this study is to evaluate the dose limiting toxicities (DLTs) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation.&#xD;
A DLT will include some Grade 3 or 4 AEs (as assessed by CTCAE version 4.03) if deemed related to study drug. In addition, any patient who is unable to receive 80% of the expected dose of CPX-POM (i.e., patients who are unable to receive at least 4 of the 5 scheduled doses) because of AEs will be considered to have a DLT.&#xD;
In order to identify any DLTs, safety assessments including AEs, physical examinations, vital signs, and clinical laboratory tests will be conducted during each study visit through Day 22.&#xD;
Participants were &quot;staged&quot; or &quot;graded&quot; clinically according to the American Joint Committee on Cancer (AJCC) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the Maximum Tolerated Dose (MTD) of CPX-POM</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 6, 10, 22 and 28</time_frame>
    <description>The primary objective of this study is to evaluate the maximum tolerated dose (MTD) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation. MTD was determined by testing increasing doses up to 1200 mg/m^2 by IV.&#xD;
The MTD is defined as the dose BELOW that dose which causes DLTs in ≥33% of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Plasma PK: Cmax (ng/mL) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Measure PK parameter Cmax (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Plasma PK: Terminal Half-life of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Determine Terminal Half-Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Plasma PK: AUCss (ng/mL/hr) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Measure PK parameter area-under-the-plasma-drug/metabolite-concentration-time curve (ng/mL/hr) following single dose (AUC) and at steady-state AUCss following single and repeat drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Plasma PK: Cls (mL/hr/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Measure PK parameter Cls (mL/hr/kg) - systemic clearance following single dose (Cls) following single and repeat drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Plasma PK: Vd and Vss (mL/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Measure PK parameters Vd (apparent volume of distribution) and Vss (steady state volume of distribution) (mL/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Plasma PK: AUCss/AUCi Accumulation Ratio of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Determine PK parameter AUC derived accumulation ratio (AUCss/AUCi ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Urine PK: Percent (%) of the CPX-POM Dose Excreted in Urine as CPX-POM and Metabolites, Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Measure Percent Dose (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Urine PK: Average 24-hour Urine Concentration of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</measure>
    <time_frame>Days 5-6</time_frame>
    <description>Measure urine CPX concentration (uM)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>CPX-POM - 30 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPX-POM - 60 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPX-POM - 120 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPX-POM - 240 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPX-POM - 360 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPX-POM - 600 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPX-POM - 900 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPX-POM - 1200 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 30 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 30 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 60 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 60 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 120 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 120 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 240 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 240 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 360 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 360 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 600 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 600 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 900 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 900 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-POM - 1200 mg/m^2</intervention_name>
    <description>CPX-POM</description>
    <arm_group_label>CPX-POM - 1200 mg/m^2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Include:&#xD;
&#xD;
          1. Patient is male or female aged ≥18 years.&#xD;
&#xD;
          2. Patient provided signed and dated informed consent prior to initiation of any study&#xD;
             procedures.&#xD;
&#xD;
          3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0&#xD;
             (fully active, able to carry out all pre-disease activities without restriction) or 1&#xD;
             (unable to perform physically strenuous activity but ambulatory and able to carry out&#xD;
             work of a light or sedentary nature).&#xD;
&#xD;
          4. Patient has a predicted life expectancy of ≥3 months.&#xD;
&#xD;
          5. Dose escalation cohorts only: Patient has adequate renal function (creatinine ≤1.5 ×&#xD;
             the upper limit of normal [ULN]) or a glomerular filtration rate (GFR) of ≥50&#xD;
             mL/min/1.73 m^2). Expansion cohort only: Patient has a GFR of ≥30 mL/min/1.73 m^2.&#xD;
&#xD;
          6. Patient has adequate hepatic function, as evidenced by a total bilirubin ≤1.5 × ULN,&#xD;
             aspartate transaminase (AST), and /or alanine transaminase (ALT) ≤3 × ULN or ≤5 ×ULN,&#xD;
             if due to liver involvement by tumor.&#xD;
&#xD;
          7. Patient has adequate bone marrow function, as evidenced by hemoglobin ≥9.0 g/dL in the&#xD;
             absence of transfusion within the previous 72 hours, platelet count ≥100×10^9cells/L,&#xD;
             and absolute neutrophil count (ANC) ≥1.5×10^9 cells/L.&#xD;
&#xD;
          8. Patient has no significant ischemic heart disease or myocardial infarction (MI) within&#xD;
             6 months before the first dose of CPX-POM and currently has adequate cardiac function,&#xD;
             as evidenced by a left ventricular ejection fraction of &gt;50% as assessed by&#xD;
             multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT&#xD;
             interval (QTc) &lt;470 msec by Fridericia (QTcF). The eligibility of patients with&#xD;
             ventricular pacemakers for whom the QT interval may not be accurately measurable will&#xD;
             be determined on a case-by-case basis by the Sponsor in consultation with the Medical&#xD;
             Monitor.&#xD;
&#xD;
          9. Patient and his/her partner agree to use adequate contraception after providing&#xD;
             written informed consent through 3 months after the last dose of CPX-POM, as follows:&#xD;
&#xD;
               1. For women: Negative pregnancy test during Screening and at Day 1 of each&#xD;
                  treatment cycle and compliant with a medically-approved contraceptive regimen&#xD;
                  during and for 3 months after the treatment period or documented to be surgically&#xD;
                  sterile or postmenopausal.&#xD;
&#xD;
               2. For men: Compliant with a medically-approved contraceptive regimen during and for&#xD;
                  3 months after the treatment period or documented to be surgically sterile. Men&#xD;
                  whose sexual partners are of child-bearing potential must agree to use 2 methods&#xD;
                  of contraception prior to study entry, during the study, and for 3 months after&#xD;
                  the treatment period.&#xD;
&#xD;
         10. Patient is willing and able to participate in the study and comply with all study&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria Include:&#xD;
&#xD;
        Patients who meet any of the following exclusion criteria are not to be enrolled in this&#xD;
        study&#xD;
&#xD;
          1. Patient has a history of risk factors for torsade de pointes (e.g., heart failure,&#xD;
             hypokalemia, family history of long QT syndrome) or requires the use of concomitant&#xD;
             medications that prolong the QT/QTc interval during study participation. Patients&#xD;
             should not receive anti-emetic medications before and following Dose 1 of Cycle 1 for&#xD;
             each treatment cohort. However, anti-emetics such as ondansetron or granisetron that&#xD;
             have a mild QTc prolonging effect are allowed starting with Dose 2 of Cycle 1, if used&#xD;
             with caution and attention to the approved labelling.&#xD;
&#xD;
          2. Patient has an abnormal cardiac appearance/heart size, as evidenced by chest X-ray or&#xD;
             computed tomography (CT) scan.&#xD;
&#xD;
          3. Patient has an uncontrolled or severe intercurrent medical condition (including&#xD;
             uncontrolled brain metastases). Patients with stable brain metastases either treated&#xD;
             or being treated with a stable dose of steroids/anticonvulsants, with no dose change&#xD;
             within 4 weeks before the first dose of CPX-POM and no anticipated dose change, are&#xD;
             allowed. The decision to exclude a patient from the study for an uncontrolled or&#xD;
             severe intercurrent medical condition will be made by the Principal Investigator.&#xD;
             Examples could include epilepsy, resistant infection, or any other neurological&#xD;
             disease that would make clinical assessment difficult.&#xD;
&#xD;
          4. Patient underwent major surgery within 4 weeks before the first dose of CPX-POM or&#xD;
             received cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy,&#xD;
             biologic or immunotherapy, etc.) or an drug or device within 4 weeks (6 weeks for&#xD;
             mitomycin C and nitrosoureas) or 5 half-lives of that agent (whichever is shorter)&#xD;
             before the first dose of CPX-POM. A minimum of 10 days between termination of the&#xD;
             investigational drug and administration of CPX-POM is required. In addition, any&#xD;
             drug-related toxicity, with the exception of alopecia, should have recovered to ≤Grade&#xD;
             1.&#xD;
&#xD;
          5. If female, patient is pregnant or breast-feeding.&#xD;
&#xD;
          6. Patient has evidence of a serious active infection (e.g., infection requiring&#xD;
             treatment with intravenous antibiotics).&#xD;
&#xD;
          7. Patient has active Hepatitis A infection.&#xD;
&#xD;
          8. Patient known human immunodeficiency virus (HIV) or Hepatitis B or C infection, as&#xD;
             such patients may be at increased risk for toxicity due to concomitant treatment and&#xD;
             disease-related symptoms may preclude accurate assessment of the safety of CPX POM.&#xD;
&#xD;
          9. Patient has an important medical illness or abnormal laboratory finding that, in the&#xD;
             Investigator's opinion, would increase the risk of participating in this study.&#xD;
&#xD;
         10. Patient is taking warfarin.&#xD;
&#xD;
         11. Patient has a history of other malignancy treated with curative intent within the&#xD;
             previous 5 years with the exception of adequately treated non-melanoma skin cancer or&#xD;
             carcinoma in situ of the cervix. Patients with previous invasive cancers are eligible&#xD;
             if the treatment was completed more than 5 years prior to initiating current study&#xD;
             treatment, and there is no evidence of recurrent disease.&#xD;
&#xD;
         12. Patient has known allergy or hypersensitivity to components of CPX-POM.&#xD;
&#xD;
         13. Patient is taking any iron replacement therapy administered IV, IM, or orally due to&#xD;
             the potential for loss of anticancer activity due to drug and metabolites chelating&#xD;
             iron.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Taylor III, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <results_first_submitted>October 16, 2020</results_first_submitted>
  <results_first_submitted_qc>October 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2021</results_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03348514/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03348514/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CPX-POM - 30 mg/m^2</title>
          <description>Period 1, Dose Cohort - 30 mg/m^2</description>
        </group>
        <group group_id="P2">
          <title>CPX-POM - 60 mg/m^2</title>
          <description>Period 2, Dose Cohort - 60 mg/m^2</description>
        </group>
        <group group_id="P3">
          <title>CPX-POM - 120 mg/m^2</title>
          <description>Period 3, Dose Cohort - 120 mg/m^2</description>
        </group>
        <group group_id="P4">
          <title>CPX-POM - 240 mg/m^2</title>
          <description>Period 4, Dose Cohort - 240 mg/m^2</description>
        </group>
        <group group_id="P5">
          <title>CPX-POM - 360 mg/m^2</title>
          <description>Period 5, Dose Cohort - 360 mg/m^2</description>
        </group>
        <group group_id="P6">
          <title>CPX-POM - 600 mg/m^2</title>
          <description>Period 6, Dose Cohort - 600 mg/m^2</description>
        </group>
        <group group_id="P7">
          <title>CPX-POM - 900 mg/m^2</title>
          <description>Period 7, Dose Cohort - 900 mg/m^2</description>
        </group>
        <group group_id="P8">
          <title>CPX-POM - 1200 mg/m^2</title>
          <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CPX-POM - 30 mg/m^2</title>
          <description>Period1, Dose Cohort - 30 mg/m^2</description>
        </group>
        <group group_id="B2">
          <title>CPX-POM - 60 mg/m^2</title>
          <description>Period 2, Dose Cohort - 60 mg/m^2</description>
        </group>
        <group group_id="B3">
          <title>CPX-POM - 120 mg/m^2</title>
          <description>Period 3, Dose Cohort - 120 mg/m^2</description>
        </group>
        <group group_id="B4">
          <title>CPX-POM - 240 mg/m^2</title>
          <description>Period 4, Dose Cohort - 240 mg/m^2</description>
        </group>
        <group group_id="B5">
          <title>CPX-POM - 360 mg/m^2</title>
          <description>Period 5, Dose Cohort - 360 mg/m^2</description>
        </group>
        <group group_id="B6">
          <title>CPX-POM - 600 mg/m^2</title>
          <description>Period 6, Dose Cohort - 600 mg/m^2</description>
        </group>
        <group group_id="B7">
          <title>CPX-POM - 900 mg/m^2</title>
          <description>Period 7, Dose Cohort - 900 mg/m^2</description>
        </group>
        <group group_id="B8">
          <title>CPX-POM - 1200 mg/m^2</title>
          <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="54" lower_limit="20" upper_limit="82"/>
                    <measurement group_id="B6" value="63" lower_limit="57" upper_limit="72"/>
                    <measurement group_id="B7" value="60" lower_limit="38" upper_limit="70"/>
                    <measurement group_id="B8" value="82.5" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="B9" value="63" lower_limit="20" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and Neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM</title>
        <description>The primary objective of this study is to evaluate the dose limiting toxicities (DLTs) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation.&#xD;
A DLT will include some Grade 3 or 4 AEs (as assessed by CTCAE version 4.03) if deemed related to study drug. In addition, any patient who is unable to receive 80% of the expected dose of CPX-POM (i.e., patients who are unable to receive at least 4 of the 5 scheduled doses) because of AEs will be considered to have a DLT.&#xD;
In order to identify any DLTs, safety assessments including AEs, physical examinations, vital signs, and clinical laboratory tests will be conducted during each study visit through Day 22.&#xD;
Participants were &quot;staged&quot; or &quot;graded&quot; clinically according to the American Joint Committee on Cancer (AJCC) criteria.</description>
        <time_frame>Up to 22 days for each cohort</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM</title>
          <description>The primary objective of this study is to evaluate the dose limiting toxicities (DLTs) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation.&#xD;
A DLT will include some Grade 3 or 4 AEs (as assessed by CTCAE version 4.03) if deemed related to study drug. In addition, any patient who is unable to receive 80% of the expected dose of CPX-POM (i.e., patients who are unable to receive at least 4 of the 5 scheduled doses) because of AEs will be considered to have a DLT.&#xD;
In order to identify any DLTs, safety assessments including AEs, physical examinations, vital signs, and clinical laboratory tests will be conducted during each study visit through Day 22.&#xD;
Participants were &quot;staged&quot; or &quot;graded&quot; clinically according to the American Joint Committee on Cancer (AJCC) criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Determine the Maximum Tolerated Dose (MTD) of CPX-POM</title>
        <description>The primary objective of this study is to evaluate the maximum tolerated dose (MTD) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation. MTD was determined by testing increasing doses up to 1200 mg/m^2 by IV.&#xD;
The MTD is defined as the dose BELOW that dose which causes DLTs in ≥33% of patients.</description>
        <time_frame>Days 1, 2, 3, 4, 5, 6, 10, 22 and 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received at least one dose of CPX-POM either at 30 mg/m^2, 60 mg/m^2, 120 mg/m^2, 240 mg/m^2, 360 mg/m^2, 600 mg/m^2, 900 mg/m^2 and 1200 mg/m^2 via IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Maximum Tolerated Dose (MTD) of CPX-POM</title>
          <description>The primary objective of this study is to evaluate the maximum tolerated dose (MTD) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation. MTD was determined by testing increasing doses up to 1200 mg/m^2 by IV.&#xD;
The MTD is defined as the dose BELOW that dose which causes DLTs in ≥33% of patients.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Plasma PK: Cmax (ng/mL) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Measure PK parameter Cmax (ng/mL)</description>
        <time_frame>Days 5-6</time_frame>
        <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Cohort Dose - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Cohort Dose - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Plasma PK: Cmax (ng/mL) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Measure PK parameter Cmax (ng/mL)</description>
          <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371"/>
                    <measurement group_id="O2" value="1935"/>
                    <measurement group_id="O3" value="3491"/>
                    <measurement group_id="O4" value="6792"/>
                    <measurement group_id="O5" value="5297" spread="1182"/>
                    <measurement group_id="O6" value="9457" spread="512"/>
                    <measurement group_id="O7" value="17277" spread="1913"/>
                    <measurement group_id="O8" value="15970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Plasma PK: Terminal Half-life of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Determine Terminal Half-Life</description>
        <time_frame>Days 5-6</time_frame>
        <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Plasma PK: Terminal Half-life of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Determine Terminal Half-Life</description>
          <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34"/>
                    <measurement group_id="O2" value="0.54"/>
                    <measurement group_id="O3" value="5.56"/>
                    <measurement group_id="O4" value="3.34"/>
                    <measurement group_id="O5" value="3.12" spread="1.34"/>
                    <measurement group_id="O6" value="4.61" spread="1.46"/>
                    <measurement group_id="O7" value="8.30" spread="2.63"/>
                    <measurement group_id="O8" value="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Plasma PK: AUCss (ng/mL/hr) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Measure PK parameter area-under-the-plasma-drug/metabolite-concentration-time curve (ng/mL/hr) following single dose (AUC) and at steady-state AUCss following single and repeat drug administration.</description>
        <time_frame>Days 5-6</time_frame>
        <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Plasma PK: AUCss (ng/mL/hr) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Measure PK parameter area-under-the-plasma-drug/metabolite-concentration-time curve (ng/mL/hr) following single dose (AUC) and at steady-state AUCss following single and repeat drug administration.</description>
          <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Dose AUCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589"/>
                    <measurement group_id="O2" value="1262"/>
                    <measurement group_id="O3" value="3736"/>
                    <measurement group_id="O4" value="4622"/>
                    <measurement group_id="O5" value="4731" spread="1310"/>
                    <measurement group_id="O6" value="11914" spread="1852"/>
                    <measurement group_id="O7" value="24148" spread="6067"/>
                    <measurement group_id="O8" value="34470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Steady State AUCss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="515"/>
                    <measurement group_id="O2" value="1328"/>
                    <measurement group_id="O3" value="5143"/>
                    <measurement group_id="O4" value="6000"/>
                    <measurement group_id="O5" value="4856" spread="910"/>
                    <measurement group_id="O6" value="12484" spread="1182"/>
                    <measurement group_id="O7" value="23414" spread="1913"/>
                    <measurement group_id="O8" value="28048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Plasma PK: Cls (mL/hr/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Measure PK parameter Cls (mL/hr/kg) - systemic clearance following single dose (Cls) following single and repeat drug administration.</description>
        <time_frame>Days 5-6</time_frame>
        <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Plasma PK: Cls (mL/hr/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Measure PK parameter Cls (mL/hr/kg) - systemic clearance following single dose (Cls) following single and repeat drug administration.</description>
          <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
          <units>mL/hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Dose Cls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614"/>
                    <measurement group_id="O2" value="581"/>
                    <measurement group_id="O3" value="361"/>
                    <measurement group_id="O4" value="515"/>
                    <measurement group_id="O5" value="1065" spread="435"/>
                    <measurement group_id="O6" value="507" spread="95"/>
                    <measurement group_id="O7" value="432" spread="142"/>
                    <measurement group_id="O8" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Steady State Cls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="702"/>
                    <measurement group_id="O2" value="552"/>
                    <measurement group_id="O3" value="262"/>
                    <measurement group_id="O4" value="397"/>
                    <measurement group_id="O5" value="963" spread="271"/>
                    <measurement group_id="O6" value="471" spread="113"/>
                    <measurement group_id="O7" value="421" spread="184"/>
                    <measurement group_id="O8" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Plasma PK: Vd and Vss (mL/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Measure PK parameters Vd (apparent volume of distribution) and Vss (steady state volume of distribution) (mL/kg)</description>
        <time_frame>Days 5-6</time_frame>
        <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Plasma PK: Vd and Vss (mL/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Measure PK parameters Vd (apparent volume of distribution) and Vss (steady state volume of distribution) (mL/kg)</description>
          <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2370"/>
                    <measurement group_id="O2" value="429"/>
                    <measurement group_id="O3" value="2100"/>
                    <measurement group_id="O4" value="1966"/>
                    <measurement group_id="O5" value="4522" spread="2715"/>
                    <measurement group_id="O6" value="3090" spread="1015"/>
                    <measurement group_id="O7" value="5340" spread="3935"/>
                    <measurement group_id="O8" value="4887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2053"/>
                    <measurement group_id="O2" value="473"/>
                    <measurement group_id="O3" value="1633"/>
                    <measurement group_id="O4" value="736"/>
                    <measurement group_id="O5" value="1986" spread="802"/>
                    <measurement group_id="O6" value="1346" spread="349"/>
                    <measurement group_id="O7" value="2261" spread="1249"/>
                    <measurement group_id="O8" value="2518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Plasma PK: AUCss/AUCi Accumulation Ratio of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Determine PK parameter AUC derived accumulation ratio (AUCss/AUCi ratio)</description>
        <time_frame>Days 5-6</time_frame>
        <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Plasma PK: AUCss/AUCi Accumulation Ratio of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Determine PK parameter AUC derived accumulation ratio (AUCss/AUCi ratio)</description>
          <population>Pharmacokinetic data not obtained in one patient receiving 1200 mg/m^2</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86"/>
                    <measurement group_id="O2" value="1.05"/>
                    <measurement group_id="O3" value="1.59"/>
                    <measurement group_id="O4" value="1.30"/>
                    <measurement group_id="O5" value="1.08" spread="0.14"/>
                    <measurement group_id="O6" value="1.09" spread="0.17"/>
                    <measurement group_id="O7" value="1.03" spread="0.29"/>
                    <measurement group_id="O8" value="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Urine PK: Percent (%) of the CPX-POM Dose Excreted in Urine as CPX-POM and Metabolites, Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Measure Percent Dose (%)</description>
        <time_frame>Days 5-6</time_frame>
        <population>Urine pharmacokinetic data not obtained in one patient receiving 600 mg/m^2 and one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Urine PK: Percent (%) of the CPX-POM Dose Excreted in Urine as CPX-POM and Metabolites, Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Measure Percent Dose (%)</description>
          <population>Urine pharmacokinetic data not obtained in one patient receiving 600 mg/m^2 and one patient receiving 1200 mg/m^2</population>
          <units>Percent of CPX-POM dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% CPX-POM Dose Excreted as CPX-POM over 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% CPX-POM Dose Excreted as ciclopirox over 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81"/>
                    <measurement group_id="O2" value="0.82"/>
                    <measurement group_id="O3" value="1.74"/>
                    <measurement group_id="O4" value="1.25"/>
                    <measurement group_id="O5" value="0.80" spread="0.21"/>
                    <measurement group_id="O6" value="1.21" spread="0.11"/>
                    <measurement group_id="O7" value="4.42" spread="4.68"/>
                    <measurement group_id="O8" value="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% CPX-POM Dose Excreted as ciclopirox glucuronide over 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.74"/>
                    <measurement group_id="O2" value="69.73"/>
                    <measurement group_id="O3" value="70.21"/>
                    <measurement group_id="O4" value="73.86"/>
                    <measurement group_id="O5" value="75.99" spread="10.40"/>
                    <measurement group_id="O6" value="50.70" spread="29.28"/>
                    <measurement group_id="O7" value="69.62" spread="15.16"/>
                    <measurement group_id="O8" value="68.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Urine PK: Average 24-hour Urine Concentration of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
        <description>Measure urine CPX concentration (uM)</description>
        <time_frame>Days 5-6</time_frame>
        <population>Urine pharmacokinetic data not obtained in one patient receiving 600 mg/m^2 and one patient receiving 1200 mg/m^2</population>
        <group_list>
          <group group_id="O1">
            <title>CPX-POM - 30 mg/m^2</title>
            <description>Period 1, Dose Cohort - 30 mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>CPX-POM - 60 mg/m^2</title>
            <description>Period 2, Dose Cohort - 60 mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>CPX-POM - 120 mg/m^2</title>
            <description>Period 3, Dose Cohort - 120 mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>CPX-POM - 240 mg/m^2</title>
            <description>Period 4, Dose Cohort - 240 mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>CPX-POM - 360 mg/m^2</title>
            <description>Period 5, Dose Cohort - 360 mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>CPX-POM - 600 mg/m^2</title>
            <description>Period 6, Dose Cohort - 600 mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>CPX-POM - 900 mg/m^2</title>
            <description>Period 7, Dose Cohort - 900 mg/m^2</description>
          </group>
          <group group_id="O8">
            <title>CPX-POM - 1200 mg/m^2</title>
            <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Urine PK: Average 24-hour Urine Concentration of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.</title>
          <description>Measure urine CPX concentration (uM)</description>
          <population>Urine pharmacokinetic data not obtained in one patient receiving 600 mg/m^2 and one patient receiving 1200 mg/m^2</population>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65"/>
                    <measurement group_id="O2" value="0.84"/>
                    <measurement group_id="O3" value="10.77"/>
                    <measurement group_id="O4" value="3.93"/>
                    <measurement group_id="O5" value="5.10" spread="0.86"/>
                    <measurement group_id="O6" value="22.91" spread="12.83"/>
                    <measurement group_id="O7" value="138.17" spread="157.97"/>
                    <measurement group_id="O8" value="208.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CPX-POM - 30 mg/m^2</title>
          <description>Period 1, Dose Cohort - 30 mg/m^2</description>
        </group>
        <group group_id="E2">
          <title>CPX-POM - 60 mg/m^2</title>
          <description>Period 2, Dose Cohort - 60 mg/m^2</description>
        </group>
        <group group_id="E3">
          <title>CPX-POM - 120 mg/m^2</title>
          <description>Period 3, Dose Cohort - 120 mg/m^2</description>
        </group>
        <group group_id="E4">
          <title>CPX-POM - 240 mg/m^2</title>
          <description>Period 4, Dose Cohort - 240 mg/m^2</description>
        </group>
        <group group_id="E5">
          <title>CPX-POM - 360 mg/m^2</title>
          <description>Period 5, Dose Cohort - 360 mg/m^2</description>
        </group>
        <group group_id="E6">
          <title>CPX-POM - 600 mg/m^2</title>
          <description>Period 6, Dose Cohort - 600 mg/m^2</description>
        </group>
        <group group_id="E7">
          <title>CPX-POM - 900 mg/m^2</title>
          <description>Period 7 Dose Cohort - 900 mg/m^2</description>
        </group>
        <group group_id="E8">
          <title>CPX-POM - 1200 mg/m^2</title>
          <description>Period 8, Dose Cohort - 1200 mg/m^2</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Non cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Taste Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John A Taylor III</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-8170</phone>
      <email>Jtaylor27@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

